WO2007007182A3 - Formes galeniques solides d'agent antiepileptique - Google Patents

Formes galeniques solides d'agent antiepileptique Download PDF

Info

Publication number
WO2007007182A3
WO2007007182A3 PCT/IB2006/001949 IB2006001949W WO2007007182A3 WO 2007007182 A3 WO2007007182 A3 WO 2007007182A3 IB 2006001949 W IB2006001949 W IB 2006001949W WO 2007007182 A3 WO2007007182 A3 WO 2007007182A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
solid
liquid dosage
antiepileptic agent
relates
Prior art date
Application number
PCT/IB2006/001949
Other languages
English (en)
Other versions
WO2007007182A2 (fr
Inventor
Umesh Setty
Mohinder Paul Pakhetra
Ashish Gogia
Kishor Deo
Uttam Kumar Ray
Srikanth Guntupalli
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Umesh Setty
Mohinder Paul Pakhetra
Ashish Gogia
Kishor Deo
Uttam Kumar Ray
Srikanth Guntupalli
Sivakumaran Meenakshisunderam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd, Umesh Setty, Mohinder Paul Pakhetra, Ashish Gogia, Kishor Deo, Uttam Kumar Ray, Srikanth Guntupalli, Sivakumaran Meenakshisunderam filed Critical Aurobindo Pharma Ltd
Publication of WO2007007182A2 publication Critical patent/WO2007007182A2/fr
Publication of WO2007007182A3 publication Critical patent/WO2007007182A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formes galéniques orales d'un agent antiépileptique. Plus particulièrement, l'invention concerne des formes galéniques orales d'oxcarbazépine ou les sels d'oxcarbazépine acceptables sur le plan pharmaceutique. Par ailleurs, l'invention concerne un procédé de préparation des formes galéniques orales d'oxcarbazépine ou des sels d'oxcarbazépine acceptables sur le plan pharmaceutique.
PCT/IB2006/001949 2005-07-08 2006-07-05 Formes galeniques solides d'agent antiepileptique WO2007007182A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN905/CHE/2005 2005-07-08
IN905CH2005 2005-07-08
IN995/CHE/2005 2005-07-25
IN995CH2005 2005-07-25
IN1935/CHE/2005 2005-12-27
IN1935CH2005 2005-12-27
IN311CH2006 2006-02-24
IN311/CHE/2006 2006-02-24

Publications (2)

Publication Number Publication Date
WO2007007182A2 WO2007007182A2 (fr) 2007-01-18
WO2007007182A3 true WO2007007182A3 (fr) 2007-08-23

Family

ID=37564047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001949 WO2007007182A2 (fr) 2005-07-08 2006-07-05 Formes galeniques solides d'agent antiepileptique

Country Status (1)

Country Link
WO (1) WO2007007182A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987618A (zh) * 2013-03-29 2018-05-04 罗盖特公司 用于固体形式的包膜的成膜组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007211210A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007121523A1 (fr) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Composition pharmaceutique d'oxcarbazépine À PARTICULES DE 15 À 30 microns EN moyenne
WO2008037044A1 (fr) * 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Formulation orale contenant oxcarbazépine et son procédé de production
CA2773249A1 (fr) * 2009-09-10 2011-03-17 Bial-Portela & C.A., S.A. Formulations de suspension orales d?acetate d?eslicarbazepine
AR125970A1 (es) * 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435826A1 (fr) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Solutions intraveineuses pour l'épilepsie
WO2002094774A2 (fr) * 2001-05-18 2002-11-28 Ranbaxy Laboratories Limited Formes galeniques d'oxcarbazepine
US20030190361A1 (en) * 1997-02-14 2003-10-09 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1437127A1 (fr) * 1999-12-20 2004-07-14 Novartis AG Suspension d'oxcarbazépine
WO2006046105A1 (fr) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Formes de dosage de l'oxcarbazepine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435826A1 (fr) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Solutions intraveineuses pour l'épilepsie
US20030190361A1 (en) * 1997-02-14 2003-10-09 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1437127A1 (fr) * 1999-12-20 2004-07-14 Novartis AG Suspension d'oxcarbazépine
WO2002094774A2 (fr) * 2001-05-18 2002-11-28 Ranbaxy Laboratories Limited Formes galeniques d'oxcarbazepine
WO2006046105A1 (fr) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Formes de dosage de l'oxcarbazepine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHICHT S ET AL: "PHARMCOKINETICSOF OXCARBAZEPINE IN THE DOG", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 19, no. 1, February 1996 (1996-02-01), pages 27 - 31, XP000998533, ISSN: 0140-7783 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987618A (zh) * 2013-03-29 2018-05-04 罗盖特公司 用于固体形式的包膜的成膜组合物

Also Published As

Publication number Publication date
WO2007007182A2 (fr) 2007-01-18

Similar Documents

Publication Publication Date Title
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
AP2006003521A0 (en) Y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
SI1695710T1 (sl) Kristalna oblika beta-d ivabradin-hidroklorida, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
ME01394B (fr) Forme cristalline gamma-d du chlorhydrate del'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent
WO2009084024A3 (fr) Procédé pour la préparation de r-sitagliptine et de ses sels pharmaceutiquement acceptables
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
SI1598333T1 (sl) Postopek za pripravo (1s)-4,5-dimetoksi-1-(metilaminometil)-benzociklobutana in njegovih adicijskih soli, kot tudi uporaba za sintezo ivabradina in njegovih adicijskih soli s farmacevtsko sprejemljivo kislino
WO2006131591A3 (fr) Forme posologique destinee a etre administree par voie orale
ME02026B (fr) Nouvelle forme cristalline V de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
WO2008044243A3 (fr) Nouveau procédé de préparation de statines et leurs sels pharmaceutiquement acceptables
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
LT2210872T (lt) Nauja kristalinė aglometino forma iii, jos gamybos būdas ir ją turinčios farmacinės kompozicijos
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2007144169A3 (fr) Dérivés d'entacapone
WO2007007182A3 (fr) Formes galeniques solides d'agent antiepileptique
SI1846376T1 (sl) Postopek priprave 10, 11-dihidro-10-hidroksi-5H-dibenz/b,f/azepin-5- karboksamida
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2003026610A3 (fr) Procede de preparation d'une forme posologique a dissolution rapide
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques
NO20064783L (no) Opplosningstabeletter med licarbazepin
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
WO2007144699A3 (fr) Procédé pour la préparation d'alfuzosine
WO2009013594A3 (fr) Procédé de préparation de compositions solides à libération contrôlée contenant de l'oxcarbazépine, et compositions obtenues par ce procédé
WO2007110765A3 (fr) Procedes de preparation d'octreotide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765636

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765636

Country of ref document: EP

Kind code of ref document: A2